Europe
New data also suggest an improvement in pruritus – a major symptom of PBC – with a median change in VAS of -24% (80mg) and -49% (120mg) vs. -7% (placebo)
There is a tendency to look at biotech as being all about developing drugs. And, of course, that is the primary focus of BioSpace. However, from time to time it’s a good idea to remind ourselves that biotech can and does have broader applications besides medicines, and can, in fact, impact our daily lives on a regular basis.
An analysis of efficacy outcomes by causative pathogens showed that clinical and microbiologic response rates for Zerbaxa were comparable to meropenem for Gram-negative respiratory tract pathogens.
Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that its ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).
NOXXON Pharma N.V. announced its financial results for the fiscal year ending December 31, 2018.
Polyphor AG shareholders approved all motions put forward by the Board of Directors to the 22nd Annual General Meeting in Basel.
The shareholders in Recipharm AB (publ), reg. no. 556498-8425, are hereby invited to attend the Annual General Meeting (“AGM”) to be held on Monday 13 May 2019 at 3.00 pm at IVA Konferenscenter, Grev Turegatan 16 in Stockholm, Sweden.
The new accounting standard, IFRS 16 will have an estimated positive impact on EBITDA of SEK 90 million in 2019.
Gyroscope Therapeutics, headquartered in Stevenage, UK, is merging with Ambler, Pennsylvania-based Orbit Biomedical. They will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.
The companies will collaborate on a clinical trial to combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of NASH.
PRESS RELEASES